乌帕替尼对比阿达木单抗治疗类风湿关节炎的长期安全性与疗效:3期随机SELECT-COMPARE研究5年数据
SELECT-COMPARE研究5年数据显示,乌帕替尼15 mg每日一次对比阿达木单抗40 mg隔周一次(均联用甲氨蝶呤)治疗甲氨蝶呤反应不足的类风湿关节炎患者,不良事件发生率总体相似,乌帕替尼组带状疱疹、淋巴细胞减少、肌酸磷酸激酶升高、肝脏疾病及非黑色素瘤皮肤癌数值上更高;第264周临床缓解率乌帕替尼数值上更高,第192周影像学进展数值上更低。
要点
- 乌帕替尼组与阿达木单抗组不良事件发生率总体相似,乌帕替尼组带状疱疹、淋巴细胞减少、肌酸磷酸激酶升高、肝脏疾病及非黑色素瘤皮肤癌数值上更高。
- 第192周持续乌帕替尼组影像学进展数值上低于阿达木单抗组。
核心结论
- 乌帕替尼5年安全性特征与已知安全性特征一致,无新发安全风险。
- 第5年时乌帕替尼组临床应答数值上高于阿达木单抗组。
- 乌帕替尼对长期类风湿关节炎治疗表现出有利的风险-获益特征。
研究设计与样本
- SELECT-COMPARE为3期随机对照研究,纳入甲氨蝶呤反应不足的类风湿关节炎患者。
- 患者随机接受乌帕替尼15 mg每日一次、安慰剂或阿达木单抗40 mg隔周一次,均联用甲氨蝶呤。
- 第26周随机治疗应答不足者接受补救治疗,仍在安慰剂组者换用乌帕替尼;完成48周双盲期者可进入长期扩展研究。
- 安全性与疗效评估至第264周,影像学进展分析至第192周。
- 安全性采用治疗中出现的不良事件(TEAE)评估,疗效按随机分组(无应答者插补,NRI)或治疗序列(按观察值)分析。
主要发现
- 乌帕替尼组与阿达木单抗组TEAE发生率总体相似,但乌帕替尼组带状疱疹、淋巴细胞减少、肌酸磷酸激酶升高、肝脏疾病及非黑色素瘤皮肤癌报告率数值上更高。
- 第192周持续乌帕替尼组影像学进展数值上低于阿达木单抗组。
关键数值与推荐
- CDAI缓解定义为≤2.8,第264周乌帕替尼组24.6% vs 阿达木单抗组18.7%(名义p=0.042,NRI)。
- 乌帕替尼剂量为15 mg每日一次,阿达木单抗为40 mg隔周一次,均联用甲氨蝶呤。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the safety and efficacy of upadacitinib versus adalimumab from SELECT-COMPARE over 5 years. METHODS: Patients with rheumatoid arthritis and inadequate response to methotrexate were randomised to receive upadacitinib 15 mg once daily, placebo or adalimumab 40 mg every other week, all with concomitant methotrexate. By week 26, patients with insufficient response to randomised treatment were rescued; patients remaining on placebo switched to upadacitinib. Patients completing the 48-week double-blind period could enter a long-term extension. Safety and efficacy were assessed through week 264, with radiographic progression analysed through week 192. Safety was assessed by treatment-emergent adverse events (TEAEs). Efficacy was analysed by randomised group (non-responder imputation (NRI)) or treatment sequence (as observed). RESULTS: Rates of TEAEs were generally similar with upadacitinib versus adalimumab, although numerically higher rates of herpes zoster, lymphopenia, creatine phosphokinase elevation, hepatic disorder and non-melanoma skin cancer were reported with upadacitinib. Numerically greater proportions of patients randomised to upadacitinib versus adalimumab achieved clinical responses (NRI); Clinical Disease Activity Index remission (≤2.8) and Disease Activity Score based on C reactive protein <2.6 were achieved by 24.6% vs 18.7% (nominal p=0.042) and 31.8% vs 23.2% (nominal p=0.006), respectively. Radiographic progression was numerically lower with continuous upadacitinib versus adalimumab at week 192. CONCLUSION: The safety profile of upadacitinib through 5 years was consistent with the known safety profile of upadacitinib, with no new safety risks. Clinical responses were numerically higher with upadacitinib versus adalimumab at 5 years. Upadacitinib demonstrates a favourable benefit-risk profile for long-term rheumatoid arthritis treatment. TRIAL REGISTRATION NUMBER: NCT02629159.
引用
- Fleischmann R, Swierkot J, Penn SK, et al. Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study. RMD Open. 2024. PMID: 38806190. doi:10.1136/rmdopen-2023-004007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。